Skip to main content

A prime boost strategy for immunotherapy of breast and ovarian cancer

Objective

This project aims to develop a protocol for effective immunotherapy of breast and ovarian cancer based on a prime boost strategy and the MUC1 antigen which is over-expressed and aberrantly glycosylated in 90% of these malignancies. The strategy will combine cDNA priming with a glycoprotein boost. Different cancer-associated glycoforms of MUC1 will be produced in CHO cells, wild type, and modified by transfection of specific glycosyl transferases. The glycoproteins will be purified, characterised and comparatively evaluated with MUC1 cDNA for efficacy in tumour rejection in mouse models. Chemo-enzymically synthesised MUC1 glycopeptides will be used to evaluate immune responses. Conditions for production to GMP standard of MUC1 cDNA and the selected glycoprotein will be established to prepare for a clinical study. The pattern of glycosylation in cancer cells will be defined with microarray technology and MUC1 cDNA modified.

Funding Scheme

CSC - Cost-sharing contracts
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CANCER RESEARCH UK
Address
Lincoln's Inn Field 61
WC2A 3PX London
United Kingdom

Participants (7)

CANCER RESEARCH TECHNOLOGY LIMITED
United Kingdom
Address
Dominion House, St-bartholomew's Hospital, 59 Bart
EC1A 7BE London
FORSCHUNGSZENTRUM JUELICH GMBH
Germany
Address

52425 Juelich
GOETEBORG UNIVERSITY
Sweden
Address
9,Medicinaregatan 9
405 30 Goeteborg
UNIVERSITY OF COPENHAGEN
Denmark
Address
20,Noerre Allee 20
2200 Koepenhagen
UNIVERSITY OF ROME "LA SAPIENZA"
Italy
Address
Viale Regina Elena 324
00161 Roma
UNIVERSITY OF UMEAA
Sweden
Address
90187,Universitetsomradet, Naturvetarhuset
901 57 Umeaa
UNIVERSITY OF ZURICH
Switzerland
Address
30,Gloriastrasse 30
8028 Zurich